[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:oropharyngeal-carcinoma:hpv":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Oropharyngeal Carcinoma","HPV",20,[8,16,22,28,34,40,46,52,58,64,70,76,83,90,96,102,108,114,121,128],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07178301","Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial",[12],"Phase 2","RECRUITING","2026-08-26T02:15:58.452248Z","2026-07-19T19:36:05.065224Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06984861","A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer",[12],"2026-08-26T02:16:27.227548Z","2026-05-05T02:43:29.643338Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06554158","De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers",[],"2026-08-26T02:16:05.813655Z","2026-05-05T02:43:29.477332Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT06702033","The Minimalist Trial-2",[12],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:29.138139Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":38,"content_modified":39},"NCT03215719","Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma",[12],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:29.074089Z",{"nct_id":41,"title":42,"phases":43,"status":13,"updated_at":44,"content_modified":45},"NCT05894083","A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)",[12],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:28.218746Z",{"nct_id":47,"title":48,"phases":49,"status":13,"updated_at":50,"content_modified":51},"NCT05799144","pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w\u002FAdvanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer",[12],"2026-08-26T02:16:10.529598Z","2026-05-05T02:43:28.217841Z",{"nct_id":53,"title":54,"phases":55,"status":13,"updated_at":56,"content_modified":57},"NCT06902623","Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy",[],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:27.405933Z",{"nct_id":59,"title":60,"phases":61,"status":13,"updated_at":62,"content_modified":63},"NCT05491512","A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer",[12],"2026-08-26T02:16:09.452956Z","2026-05-05T02:43:27.316218Z",{"nct_id":65,"title":66,"phases":67,"status":13,"updated_at":68,"content_modified":69},"NCT07290621","Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer",[12],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:26.936724Z",{"nct_id":71,"title":72,"phases":73,"status":13,"updated_at":74,"content_modified":75},"NCT06445114","Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer",[12],"2026-08-26T02:17:27.435233Z","2026-04-29T02:57:57.120187Z",{"nct_id":77,"title":78,"phases":79,"status":13,"updated_at":81,"content_modified":82},"NCT06319963","A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer",[80],"Phase 1\u002FPhase 2","2026-08-26T02:18:00.873391Z","2026-05-05T02:43:28.173901Z",{"nct_id":84,"title":85,"phases":86,"status":13,"updated_at":88,"content_modified":89},"NCT05172245","Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer",[87],"Phase 1","2026-08-26T02:17:41.695983Z","2026-07-19T19:36:05.120891Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT05686226","E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers",[12],"2026-08-26T02:15:28.524219Z","2026-07-05T05:32:16.812867Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT05639972","E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers",[80],"2026-08-26T02:17:33.002248Z","2026-07-05T05:32:16.809101Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT05880797","Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma",[],"2026-08-26T02:19:04.543908Z","2026-05-13T02:55:06.390798Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT03010150","Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer",[],"2026-08-26T02:16:32.589113Z","2026-05-13T02:55:06.106681Z",{"nct_id":115,"title":116,"phases":117,"status":118,"updated_at":119,"content_modified":120},"NCT04444869","Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer",[12],"UNKNOWN","2026-08-03T01:56:19.375288Z","2026-05-05T02:43:27.629541Z",{"nct_id":122,"title":123,"phases":124,"status":125,"updated_at":126,"content_modified":127},"NCT04667585","Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx",[],"ACTIVE_NOT_RECRUITING","2026-08-03T02:35:59.254098Z","2026-05-05T02:43:27.433162Z",{"nct_id":129,"title":130,"phases":131,"status":125,"updated_at":132,"content_modified":133},"NCT05787639","Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)",[12],"2026-08-03T03:02:32.170340Z","2026-05-05T02:43:26.748629Z"]